To Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa (HIDRI2007)
Read time: 2 mins
Last updated:1st Feb 2007
The trial is a 12-week phase 2 study. Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12 in subjects with moderate to severe hidradenitis suppurativa.
|Date last updated at source||2009-01-22|
|Study start date||2007-02-01|
|Estimated primary completion date||2008-08-01|